retatrutide trial weight loss results Lilly's triple agonist achieves 16.8% in phase 3 retatrutide weight loss phase 2

You take it every morning on an empty stomach with just a sip of water

Long-Term Health Considerations For some individuals, especially those with obesity-related health conditions (like type 2 diabetes, high blood pressure, or cardiovascular issues), staying on GLP-1 medications for the long term might be necessary to manage overall health, not just weight loss

Retatrutide, in research terms Retatrutide, originally designated LY3437943 by Eli Lilly, is the first triple agonist to reach late-stage clinical evaluation

Medicaid spending Medicaid programs cover some GLP-1 drugs to treat obesity in at least 13 other states: California, Delaware, Kansas, Massachusetts, Michigan, Minnesota, Mississippi, New Hampshire, Pennsylvania, Rhode Island, South Carolina, Virginia and Wisconsin

Together, these actions help keep blood sugar steady and reduce overeating

Unfortunately, misinformation about these medications has also taken the Internet by storm